Li Jinyu, You Junhao, Si Wen, Zhu Yanyun, Chen Yi, Yang Bo, Han Chun, Linghu Ruixia, Zhang Xingyang, Jiao Shunchang, Yang Junlan
From the Department of Medical Oncology (JL, WS, YZ, RL, XZ, SJ, JY, BY, CH), Chinese PLA General Hospital, Beijing; Department of Medical Oncology (JY), Hainan Branch of PLA General Hospital, Sanya; School of Medicine (WS), Nankai University, Tianjin; and Medical Center of Tsinghua University (YC), Beijing, China.
Medicine (Baltimore). 2015 Oct;94(41):e1340. doi: 10.1097/MD.0000000000001340.
The treatment efficacy of advanced breast cancer is still not promising. This study aimed to compare the efficacy and safety of docetaxel/S-1 (DS1) versus docetaxel/capecitabine (DX) as the first-line treatment for advanced breast cancer.From June 2008 to June 2013, 22 patients with advanced breast cancer were treated with the DS1 regimen. Another 26 age- and disease status-matched patients treated with the DX regimen served as controls. The 2 groups were compared in terms of time to progression (TTP), objective response rate, disease control rate, clinical benefit rate, and safety profiles.Median TTP did not differ significantly between the DS1 group and the DX group (9.04 vs 10.94 months, P = 0.473). There were no significant differences in objective response rate, disease control rate, and clinical benefit rate between the 2 groups. Both the DS1 and the DX regimens showed good tolerability. The 2 regimens showed no significant difference in adverse events except degree III hand-foot syndrome (DS1 0 vs DX 23.1%, P = 0.025).For the first-line treatment of advanced breast cancer, the DS1 and the DX regimens showed similar efficacy and safety. The DS1 regimen had less severe hand-foot syndrome than the DX regimen.
晚期乳腺癌的治疗效果仍然不容乐观。本研究旨在比较多西他赛/S-1（DS1）与多西他赛/卡培他滨（DX）作为晚期乳腺癌一线治疗方案的疗效和安全性。2008年6月至2013年6月，22例晚期乳腺癌患者接受DS1方案治疗。另外26例年龄和疾病状态匹配的患者接受DX方案治疗作为对照。比较两组的无进展生存期（TTP）、客观缓解率、疾病控制率、临床获益率和安全性。DS1组和DX组的中位TTP无显著差异（9.04个月对10.94个月，P = 0.473）。两组的客观缓解率、疾病控制率和临床获益率无显著差异。DS1和DX方案均显示出良好的耐受性。除Ⅲ度手足综合征外，两组不良事件无显著差异（DS1为0，DX为23.1%，P = 0.025）。对于晚期乳腺癌的一线治疗，DS1和DX方案显示出相似的疗效和安全性。DS1方案的手足综合征比DX方案轻。
